Adaptive Biotechnologies is in combining next-generation sequencing and expert bioinformatics to profile T-cell and B-cell receptors
PRN1008 is a highly potent and selective inhibitor of Bruton tyrosine kinase (BTK), an enzyme that plays a major role in the signaling pathway running downstream from B cells to the B-cell receptors
found on most white blood cells with the exception of T cells and plasma cells.
B-cells recognize solvent-exposed antigens through antigen receptors, named as B-cell receptors
(BCR), consisting of membrane-bound immunoglobulins, as shown in Figure 1.
The intricate enzymatic machinery needed for the recombination of T-cell and B-cell receptors
is the basis of adaptive immunity and major mutations in associated genes like RAG and Artemis invariably lead to severe combined immunodeficiency with no or very limited expression of T-cells and B-cells (T-B-SCID) [1,2].
Adaptive Biotechnologies combines high-throughput sequencing and expert bioinformatics to profile T-cell and B-cell receptors
bringing its immunosequencing platform into laboratories around the world to drive groundbreaking research in cancer and other immune-mediated diseases.
- US-based Adaptive Biotechnologies, a specialist in combining sequencing and bioinformatics to profile T- and B-cell receptors
of the adaptive immune system, has entered into a collaboration agreement with US-based biotechnology company Amgen to utilise Adaptive's NGS-based clonoSEQ Assay in the Phase 3 CANDOR study, sponsored by Amgen in collaboration with Janssen, comparing Kyprolis (carfilzomib), Darzalex (daratumumab), and dexamethasone with Kyrpolis and dexamethasone.
The immunoSEQ Assays can identify ms of T- and B-cell receptors
from a single sample in exquisite detail.
Adaptive Biotechnologies is combines Next Generation Sequencing and expert bioinformatics to profile T-cell and B-cell receptors
Adaptive Biotechnologies is in combining high-throughput sequencing and expert bioinformatics to profile T-cell and B-cell receptors